Oppenheimer Lowers Zura Bio (NASDAQ:ZURA) Price Target to $15.00

Zura Bio (NASDAQ:ZURA) had its price target dropped by equities researchers at Oppenheimer from $16.00 to $15.00 in a research note issued on Friday,Benzinga reports. The brokerage currently has an “outperform” rating on the stock. Oppenheimer’s target price points to a potential upside of 157.16% from the company’s previous close.

Other equities analysts have also issued reports about the company. Weiss Ratings restated a “sell (d-)” rating on shares of Zura Bio in a research report on Friday, January 9th. Leerink Partners upgraded Zura Bio to a “strong-buy” rating in a report on Sunday, November 23rd. Finally, Wedbush assumed coverage on shares of Zura Bio in a report on Monday, February 9th. They issued an “outperform” rating and a $15.00 price target on the stock. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $11.40.

Zura Bio Price Performance

NASDAQ ZURA traded down $0.29 on Friday, reaching $5.83. 238,620 shares of the company’s stock traded hands, compared to its average volume of 660,570. The stock has a market cap of $379.26 million, a PE ratio of -9.02 and a beta of 0.18. Zura Bio has a 12 month low of $0.97 and a 12 month high of $7.44. The stock has a 50-day simple moving average of $6.16 and a 200 day simple moving average of $4.51.

Zura Bio (NASDAQ:ZURA) last announced its quarterly earnings data on Tuesday, March 24th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.18) by ($0.02). As a group, analysts anticipate that Zura Bio will post -0.65 EPS for the current year.

Insider Transactions at Zura Bio

In other Zura Bio news, major shareholder Ai Biotechnology Llc acquired 2,000,000 shares of the company’s stock in a transaction dated Thursday, February 26th. The stock was purchased at an average price of $6.25 per share, with a total value of $12,500,000.00. Following the completion of the purchase, the insider directly owned 6,552,725 shares in the company, valued at approximately $40,954,531.25. The trade was a 43.93% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 14.23% of the company’s stock.

Institutional Investors Weigh In On Zura Bio

Hedge funds have recently made changes to their positions in the company. Allworth Financial LP purchased a new stake in Zura Bio during the fourth quarter valued at $30,000. Squarepoint Ops LLC lifted its stake in shares of Zura Bio by 34.6% during the 4th quarter. Squarepoint Ops LLC now owns 33,801 shares of the company’s stock worth $177,000 after acquiring an additional 8,680 shares during the last quarter. Bank of America Corp DE grew its position in Zura Bio by 31.9% in the 4th quarter. Bank of America Corp DE now owns 41,222 shares of the company’s stock valued at $103,000 after acquiring an additional 9,966 shares during the last quarter. Scientech Research LLC purchased a new stake in Zura Bio in the third quarter worth $45,000. Finally, State Street Corp lifted its position in shares of Zura Bio by 8.3% during the fourth quarter. State Street Corp now owns 156,363 shares of the company’s stock worth $819,000 after purchasing an additional 12,000 shares during the last quarter. 61.14% of the stock is currently owned by hedge funds and other institutional investors.

About Zura Bio

Zura Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation protein bioconjugates for therapeutic and diagnostic applications. Leveraging a proprietary platform for site-specific incorporation of non-canonical amino acids, the company aims to create highly targeted conjugates that improve drug delivery, enhance imaging contrast, and reduce off-target toxicity. Zura Bio’s technology is designed to streamline the manufacturing process by enabling precise attachment of payloads—such as cytotoxic drugs or imaging agents—to protein scaffolds without affecting their native structure or function.

The company’s research and development activities center on expanding its platform across multiple therapeutic areas, including oncology, immunology and rare diseases.